Corvus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Corvus Pharmaceuticals, Inc. on January 3, 2017. The filing reports the election of a new director to the Company's Board of Directors and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity data. The document focuses exclusively on corporate governance changes.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to seven directors.
- New Director Election: Ian T. Clark was elected as a Class III director, effective January 3, 2017. His term expires at the 2018 annual meeting of stockholders.
- Committee Assignments: Mr. Clark was appointed to the Compensation Committee and the Nominating and Corporate Governance Committee.
Compensation and Equity Grants
Mr. Clark's compensation package includes the following components:
- Cash Retainers: $35,000 annual retainer for Board service, $6,000 supplemental retainer for the Compensation Committee, and $4,000 supplemental retainer for the Nominating and Corporate Governance Committee.
- Initial Equity Grant: An option to purchase 30,000 shares of Common Stock, vesting in three equal annual installments (1/3 per year) subject to continued service.
- Annual Equity Grant Eligibility: Eligible for future annual grants of options to purchase 15,000 shares, vesting on the earlier of the first anniversary of the grant date or the next annual stockholders' meeting.
- Change in Control: All equity awards vest in full immediately prior to a change in control.
- Indemnification: The Company will enter into a standard indemnification agreement with Mr. Clark.
Outlook and Risks
The filing does not provide financial guidance, management commentary on business outlook, or specific risk factors beyond standard corporate governance disclosures. The press release regarding this appointment is attached as Exhibit 99.1 but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the background and qualifications of Ian T. Clark, specifically his prior role as Chief Executive Officer at Genentech.
- Review the Company's 2016 Equity Incentive Award Plan (referenced in the filing) for full terms of the equity grants.
- Confirm the total number of shares reserved for issuance under the Company's equity plans to assess potential dilution.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.